In leukemia cells, the administration of All-Trans Retinoic Acid (ATRA) reduced cell proliferation in conjunction with the increase in TG2 activity [13], and in CML patients, the activity of TG2 was lower in tumors than in normal cells [14]. This evidence concerns the gene TGM2 and chronic myelogenous leukemia, BCR-ABL1 positive.